Intellectual Property India Publishes Patent Application for 'Bifunctional Compounds Containing 2,5-Substituted Pyrimidine Derivatives For Degrading Cyclin-Dependent Kinase 2 Via Ubiquitin Proteasome Pathway' Filed by Nikang Therapeutics, Inc.

MUMBAI, India, June 13 -- Intellectual Property India has published a patent application (202517049136 A) filed by Nikang Therapeutics, Inc., Wilmington, U.S.A., on May 21, for 'bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway.'

Inventor(s) include Yu, Zhiyong; and Lou, Yan.

The application for the patent was published on June 13, under issue no. 24/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds."

The patent application was internationally filed on Nov. 08, 2023, under International application No.PCT/US2023/079145.

Disclaimer: Curated by HT Syndication.